{"id":40127,"date":"2022-04-16T17:27:56","date_gmt":"2022-04-16T17:27:56","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=40127"},"modified":"2026-05-05T16:22:29","modified_gmt":"2026-05-05T20:22:29","slug":"etude-de-marche-sur-les-produits-biologiques","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/fr\/competence\/etude-de-marche-sur-les-produits-biologiques\/","title":{"rendered":"Biologics Market Research: How Leaders Win Share"},"content":{"rendered":"<div class=\"sis-hero-preserved sis-injected-hero\" data-sis-injected=\"hero\">\n<h1 class=\"wp-block-heading\"><a href=\"https:\/\/www.sisinternational.com\/fr\/competence\/les-industries\/etude-de-marche-en-biologie\/\" class=\"sis-link-recovered\" data-sis-recovered=\"1\">\u00c9tude de march\u00e9 sur les produits biologiques<\/a><\/h1>\n<figure class=\"gb-block-image gb-block-image-c84c16ab\"><img loading=\"lazy\" decoding=\"async\" width=\"1456\" height=\"816\" class=\"gb-image gb-image-c84c16ab\" src=\"https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-3.jpg\" alt=\"\u00c9tudes de march\u00e9 et strat\u00e9gie internationales SIS\" title=\"DNA Genetics (3)\" srcset=\"https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-3.jpg 1456w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-3-300x168.jpg 300w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-3-1024x574.jpg 1024w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-3-768x430.jpg 768w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-3-18x10.jpg 18w\" sizes=\"auto, (max-width: 1456px) 100vw, 1456px\"><\/figure>\n<\/p>\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-dots\"\/>\n<h4 class=\"wp-block-heading\">In the fast-paced world of <a href=\"https:\/\/www.sisinternational.com\/fr\/competence\/les-industries\/etude-de-marche-en-biotechnologie\/\" class=\"sis-link-recovered\" data-sis-recovered=\"1\">biologics<\/a>, staying ahead of the curve is crucial. Biologics market research provides the data and insights necessary for businesses to thrive.<\/h4>\n<p>Cherchez-vous \u00e0 acqu\u00e9rir un avantage concurrentiel dans le domaine dynamique des produits biologiques ? <span style=\"font-size: inherit; background-color: var(--base-3); color: var(--contrast-2);\">Les \u00e9tudes de march\u00e9 sur les produits biologiques fournissent des informations essentielles sur les tendances du march\u00e9, les paysages r\u00e9glementaires et la dynamique concurrentielle. Ces informations permettent aux entreprises de d\u00e9velopper des strat\u00e9gies efficaces, d\u2019optimiser leurs op\u00e9rations et de parvenir \u00e0 une croissance durable sur le march\u00e9 des produits biologiques.<\/span><\/p>\n<h2 class=\"wp-block-heading\">Que sont les produits biologiques ?<\/h2>\n<p>Les produits biologiques comprennent le sang, les vaccins, les cellules somatiques et les tissus. La th\u00e9rapie g\u00e9nique, les composants sanguins et les prot\u00e9ines th\u00e9rapeutiques recombinantes rel\u00e8vent \u00e9galement de cette cat\u00e9gorie. Les produits biologiques proviennent des prot\u00e9ines, des sucres ou des acides nucl\u00e9iques de ces produits. Il peut s&#039;agir de m\u00e9langes complexes de ces substances ou d&#039;entit\u00e9s vivantes telles que des tissus et des cellules. La plupart des produits biologiques sont des m\u00e9langes de compos\u00e9s difficiles \u00e0 identifier. En cela, ils diff\u00e8rent de la plupart des m\u00e9dicaments. Le m\u00e9dicament moyen est issu d\u2019une synth\u00e8se chimique ; les cr\u00e9ateurs connaissent leur structure.<\/p>\n<p>Les produits biologiques font partie des th\u00e9rapies les plus avanc\u00e9es que vous puissiez trouver. Les m\u00e9decins les utilisent pour traiter de nombreuses maladies et affections. Voici des exemples d&#039;utilisations m\u00e9dicales des produits biologiques\u00a0:<\/p>\n<ul class=\"wp-block-list\">\n<li>Polyarthrite rhumato\u00efde<\/li>\n<li>Divers cancers<\/li>\n<li>La maladie de Crohn<\/li>\n<li>Crise cardiaque<\/li>\n<li>Scl\u00e9rose en plaques<\/li>\n<li>Lupus<\/li>\n<li>Migraine chronique<\/li>\n<li>An\u00e9mie<\/li>\n<li>Asthme allergique<\/li>\n<li>Fibrose kystique<\/li>\n<\/ul>\n<\/div>\n<h1>Biologics Market Research: How Leading Manufacturers Win in Specialty Therapeutics<\/h1>\n<p>Biologics now drive the majority of new specialty pharma revenue, and the firms gaining share share one trait: disciplined intelligence. Biologics market research separates teams that price into resistance from teams that secure formulary wins on launch.<\/p>\n<p>The category rewards precision. Molecules compete on indication-level efficacy, payer evidence, injection device experience, and cold chain reliability. Generic frameworks miss this. The winners commission intelligence built around the mechanism of action, the prescriber decision tree, and the payer evidence threshold for each target indication.<\/p>\n<h2>Why Biologics Market Research Demands a Different Operating Model<\/h2>\n<p>Small molecule playbooks transfer poorly. Biologics carry manufacturing complexity, narrow patient subpopulations, biomarker-driven prescribing, and biosimilar competitive intelligence requirements that begin years before loss of exclusivity. The intelligence model has to match.<\/p>\n<p>Three structural realities shape the work. Prescribing concentrates among a small set of pulmonologists, rheumatologists, oncologists, or dermatologists per market. Payer access decisions hinge on real-world evidence and HTA submission evidence rather than pivotal trial data alone. Patient adherence depends on device usability, site of care economics, and specialty pharmacy distribution.<\/p>\n<p><span style=\"color:#216896;border-left:3px solid #216896;padding-left:0.5rem;\">SIS International Research has found that competitive position in biologics correlates more tightly with KOL mapping depth and payer value story clarity than with headline efficacy data. Asthma biologics provide a clear example: IL-5 and IgE class entrants with similar clinical profiles separated on prescriber confidence, eosinophil biomarker positioning, and injection site experience rather than absolute exacerbation reduction.<\/span><\/p>\n<h2>The Intelligence Stack That Drives Biologics Launch Success<\/h2>\n<p>High-performing teams build a layered intelligence stack rather than a single tracker. Each layer answers a different commercial question and feeds a different function inside the launch organization.<\/p>\n<figure class=\"wp-block-table sis-injected-table\" data-sis-injected=\"table\">\n<table>\n<thead>\n<tr>\n<th>Intelligence Layer<\/th>\n<th>Decision It Supports<\/th>\n<th>Primary Method<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Indication prioritization<\/td>\n<td>Lifecycle sequencing<\/td>\n<td>B2B expert interviews with treating specialists<\/td>\n<\/tr>\n<tr>\n<td>KOL mapping<\/td>\n<td>Advisory board and publication strategy<\/td>\n<td>Network analysis and sentiment interviews<\/td>\n<\/tr>\n<tr>\n<td>Payer value story<\/td>\n<td>Pricing and access submissions<\/td>\n<td>Payer panels and HTA simulation<\/td>\n<\/tr>\n<tr>\n<td>Patient journey mapping<\/td>\n<td>Adherence and support program design<\/td>\n<td>Ethnographic research with treated patients<\/td>\n<\/tr>\n<tr>\n<td>Biosimilar competitive intelligence<\/td>\n<td>Defense strategy pre-LOE<\/td>\n<td>Manufacturer pipeline tracking and tender analysis<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n<p style=\"font-size:11px;color:#666;margin-top:4px;\"><em>Source: SIS International Research<\/em><\/p>\n<p>The stack matters because the questions arrive sequentially. Indication prioritization governs the trial program. KOL mapping shapes the publication plan. Payer value story drafts begin two years before approval. Patient journey work informs hub services. Biosimilar defense begins at peak sales, not at patent cliff.<\/p>\n<h2>Where Conventional Research Falls Short and What Replaces It<\/h2>\n<p>Standard syndicated reports estimate market size and rank competitors. They rarely reveal why a pulmonologist switched from omalizumab to dupilumab in moderate-to-severe atopic dermatitis with comorbid asthma, or why a German sickness fund tightened prior authorization on a specific IL-5 inhibitor. Those answers come from primary work with the actual decision makers.<\/p>\n<p>Leading manufacturers fund three categories of primary intelligence the syndicated reports cannot replicate. Structured specialist interviews across the US, Germany, Japan, and the UK quantify switching triggers and unmet need by line of therapy. Payer dossier reviews simulate HTA submission evidence against the live reference cases. Patient ethnography captures injection experience, caregiver burden, and the operational pain points that drive discontinuation.<\/p>\n<p><span style=\"color:#216896;border-left:3px solid #216896;padding-left:0.5rem;\">In structured expert interviews conducted by SIS International with senior pulmonologists and allergists across the US, Germany, and Japan, prescriber preference inside the IL-5 class shifted on three non-clinical factors: dosing interval, autoinjector reliability, and the speed of specialty pharmacy fulfillment. Headline efficacy was treated as table stakes once a molecule cleared the eosinophil threshold.<\/span><\/p>\n<h2>The Global Dimension: Why Multi-Country Design Compounds Returns<\/h2>\n<p>Biologics commercialize across regulatory regimes that price and reimburse differently. The FDA, EMA, PMDA, MHRA, NMPA, and ANVISA evaluate the same molecule against different evidence bars. A research design that treats the US as the anchor and bolts on country supplements produces blind spots in the markets that often determine global net price.<\/p>\n<p>Germany&#8217;s AMNOG benefit assessment, England&#8217;s NICE appraisal, and Japan&#8217;s Chuikyo pricing all set reference points other payers watch. France&#8217;s transparency commission scoring shapes EU pricing corridors. Disciplined teams design the global research program backward from the toughest HTA submission evidence requirement, not forward from the US label.<\/p>\n<p>SIS International&#8217;s biologics work across the US, EU5, Japan, and emerging Asia has shown that launch sequencing decisions made on US-only research overestimate ex-US net price by meaningful margins. Multi-country payer panels run in parallel produce a defensible price corridor and identify the indications where evidence generation will move the access needle.<\/p>\n<h2>The SIS Biologics Intelligence Framework<\/h2>\n<p>The framework below organizes the work most Fortune 500 biopharma teams now commission across the lifecycle. It is method-led rather than topic-led, which keeps the intelligence tied to actual launch and defense decisions.<\/p>\n<figure class=\"wp-block-table sis-injected-table\" data-sis-injected=\"table\">\n<table>\n<thead>\n<tr>\n<th>Lifecycle Stage<\/th>\n<th>Core Question<\/th>\n<th>SIS Methodology<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Pre-Phase 3<\/td>\n<td>Which indication sequence maximizes NPV?<\/td>\n<td>B2B expert interviews, real-world evidence audit<\/td>\n<\/tr>\n<tr>\n<td>Pre-launch<\/td>\n<td>What price will the strictest HTA accept?<\/td>\n<td>Payer panels across EU5 and Japan<\/td>\n<\/tr>\n<tr>\n<td>Launch<\/td>\n<td>Which prescribers convert first and why?<\/td>\n<td>KOL mapping, longitudinal specialist tracking<\/td>\n<\/tr>\n<tr>\n<td>In-market<\/td>\n<td>Where is adherence breaking?<\/td>\n<td>Patient ethnographic research, hub data triangulation<\/td>\n<\/tr>\n<tr>\n<td>Pre-LOE<\/td>\n<td>Which biosimilars threaten which channels?<\/td>\n<td>Biosimilar competitive intelligence, tender monitoring<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n<p style=\"font-size:11px;color:#666;margin-top:4px;\"><em>Source: SIS International Research<\/em><\/p>\n<h2>What Separates the Manufacturers That Win Share<\/h2>\n<figure class=\"wp-block-image size-large sis-injected-img\" data-sis-injected=\"img\"><img loading=\"lazy\" decoding=\"async\" width=\"1456\" height=\"816\" class=\"gb-image gb-image-d03949fc gb-block-image gb-block-image-ee592961\" src=\"https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-17.jpg\" alt=\"\u00c9tudes de march\u00e9 et strat\u00e9gie internationales SIS\" title=\"DNA Genetics (17)\" srcset=\"https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-17.jpg 1456w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-17-300x168.jpg 300w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-17-1024x574.jpg 1024w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-17-768x430.jpg 768w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-17-18x10.jpg 18w\" sizes=\"auto, (max-width: 1456px) 100vw, 1456px\"><\/figure>\n<p>The pattern is consistent across asthma, atopic dermatitis, IBD, plaque psoriasis, and oncology biologics. Manufacturers that gain <a href=\"https:\/\/www.sisinternational.com\/fr\/solutions\/etude-de-marche-sur-lindustrie-des-boissons-alimentaires\/etude-de-marche-de-la-biere\/\" title=\"Beer Market Research: How Brewers Win Premium Share\"  data-wpil-monitor-id=\"11683\">share treat market research<\/a> as a continuous instrument rather than a launch event. They refresh KOL mapping quarterly, rerun payer value story testing after every competitive label expansion, and run patient ethnography on a rolling cycle.<\/p>\n<p>They also integrate the intelligence. Medical affairs, market access, marketing, and competitive intelligence read from the same evidence base. The integration prevents the common failure mode in which the brand team prices for a value story the payer team has already abandoned in dossier negotiations.<\/p>\n<p>Biologics market research, done with this discipline, is the single highest-leverage commercial investment a specialty manufacturer makes. The ratio of research spend to peak sales protected is favorable across every major class SIS has profiled.<\/p>\n<h2>Where Senior Teams Take This Next<\/h2>\n<figure class=\"wp-block-image size-large sis-injected-img\" data-sis-injected=\"img\"><img loading=\"lazy\" decoding=\"async\" width=\"1456\" height=\"816\" class=\"gb-image gb-image-e73bd7b9\" src=\"https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-14.jpg\" alt=\"\u00c9tudes de march\u00e9 et strat\u00e9gie internationales SIS\" title=\"DNA Genetics (14)\" srcset=\"https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-14.jpg 1456w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-14-300x168.jpg 300w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-14-1024x574.jpg 1024w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-14-768x430.jpg 768w, https:\/\/www.sisinternational.com\/wp-content\/uploads\/2025\/09\/DNA-Genetics-14-18x10.jpg 18w\" sizes=\"auto, (max-width: 1456px) 100vw, 1456px\"><\/figure>\n<p>The teams getting biologics market research right are now extending the model into bispecifics, cell and gene therapies, and the next biosimilar wave. The methods scale. The discipline of asking the right question at the right lifecycle stage, to the right specialist or payer, in the right country, transfers cleanly into the modalities that will define the next decade of specialty therapeutics.<\/p>\n<h2 id=\"about-sis-international\" style=\"font-family:Arial,sans-serif;color:#1a3d68;\">\u00c0 propos de SIS International<\/h2>\n<p><a href=\"https:\/\/www.sisinternational.com\/fr\/\">SIS International<\/a> propose des recherches quantitatives, qualitatives et strat\u00e9giques. Nous fournissons des donn\u00e9es, des outils, des strat\u00e9gies, des rapports et des informations pour la prise de d\u00e9cision. Nous menons \u00e9galement des entretiens, des enqu\u00eates, des groupes de discussion et d\u2019autres m\u00e9thodes et approches d\u2019\u00e9tudes de march\u00e9. <a href=\"https:\/\/www.sisinternational.com\/fr\/a-propos-de-la-recherche-internationale-sis\/contact-sis-international-market-research\/\">Contactez nous<\/a> pour votre prochain projet d&#039;\u00e9tude de march\u00e9.<\/p>\n<p><!-- sis-hreflang-start -->\n<link rel=\"alternate\" hreflang=\"en-US\" href=\"https:\/\/www.sisinternational.com\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"ar\" href=\"https:\/\/www.sisinternational.com\/ar\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"zh-CN\" href=\"https:\/\/www.sisinternational.com\/zh\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"zh-HK\" href=\"https:\/\/www.sisinternational.com\/zh_hk\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"nl-NL\" href=\"https:\/\/www.sisinternational.com\/nl\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"fr-FR\" href=\"https:\/\/www.sisinternational.com\/fr\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"de-DE\" href=\"https:\/\/www.sisinternational.com\/de\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"it-IT\" href=\"https:\/\/www.sisinternational.com\/it\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"ja\" href=\"https:\/\/www.sisinternational.com\/ja\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"ko-KR\" href=\"https:\/\/www.sisinternational.com\/ko\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"pl-PL\" href=\"https:\/\/www.sisinternational.com\/pl\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"pt-BR\" href=\"https:\/\/www.sisinternational.com\/pt\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"es-ES\" href=\"https:\/\/www.sisinternational.com\/es\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"en\" href=\"https:\/\/www.sisinternational.com\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"zh\" href=\"https:\/\/www.sisinternational.com\/zh\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"nl\" href=\"https:\/\/www.sisinternational.com\/nl\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"fr\" href=\"https:\/\/www.sisinternational.com\/fr\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"de\" href=\"https:\/\/www.sisinternational.com\/de\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"it\" href=\"https:\/\/www.sisinternational.com\/it\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"ko\" href=\"https:\/\/www.sisinternational.com\/ko\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"pl\" href=\"https:\/\/www.sisinternational.com\/pl\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"pt\" href=\"https:\/\/www.sisinternational.com\/pt\/expertise\/biologics-market-research\/\" \/>\n<link rel=\"alternate\" hreflang=\"es\" href=\"https:\/\/www.sisinternational.com\/es\/expertise\/biologics-market-research\/\" \/>\n<!-- sis-hreflang-end --><\/p>\n<section class=\"sis-related-recovered\" data-sis-recovered-section=\"1\">\n<h3>Related SIS Resources<\/h3>\n<ul>\n<li><a href=\"https:\/\/www.sisinternational.com\/fr\/couverture\/les-ameriques\/etude-de-marche-en-amerique-latine\/etude-de-marche-en-guyane-francaise\/\" class=\"sis-link-recovered\">research on international regulatory practices and market<\/a><\/li>\n<li><a href=\"https:\/\/www.sisinternational.com\/fr\/couverture\/leurope-%ef%83%97\/etude-de-marche-sur-le-vatican\/\" class=\"sis-link-recovered\">market insights to enhance its clinical research<\/a><\/li>\n<li><a href=\"https:\/\/www.sisinternational.com\/fr\/couverture\/les-ameriques\/etude-de-marche-dans-les-caraibes\/etude-de-marche-saint-barthelemy\/\" class=\"sis-link-recovered\">research indicates that the market<\/a><\/li>\n<li><a href=\"https:\/\/www.sisinternational.com\/fr\/competence\/les-industries\/etude-de-marche-en-genomique\/\" class=\"sis-link-recovered\">research initiatives on biologics<\/a><\/li>\n<\/ul>\n<\/section>","protected":false},"excerpt":{"rendered":"<p>Les produits biologiques sont des th\u00e9rapies avanc\u00e9es utilis\u00e9es pour traiter diverses maladies et affections. Les produits comprennent le sang, les vaccins, les cellules somatiques et les tissus.<\/p>","protected":false},"author":1,"featured_media":69928,"parent":14514,"menu_order":108,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-40127","page","type-page","status-publish","has-post-thumbnail"],"_links":{"self":[{"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/pages\/40127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/comments?post=40127"}],"version-history":[{"count":17,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/pages\/40127\/revisions"}],"predecessor-version":[{"id":88229,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/pages\/40127\/revisions\/88229"}],"up":[{"embeddable":true,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/pages\/14514"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/media\/69928"}],"wp:attachment":[{"href":"https:\/\/www.sisinternational.com\/fr\/wp-json\/wp\/v2\/media?parent=40127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}